drugset / Trial / NCT07441993
Exploratory Study of Orelabrutinib in the Treatment of Early-stage Untreated MZL
Phase 2
Recruiting
30 enrolled
Institute of Hematology & Blood Diseases Hospital, China
Beijing Tongren Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a single-arm, multicenter, prospective, phase II study. The primary objective is to assess the efficacy and safety of orelabrutinib in treatment-naïve patients with marginal zone lymphoma.
Timeline
- Start
- 2026-01-05
- Primary completion
- 2027-12
- Completion
- 2028-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Orelabrutinib | Small molecule | 150 mg | Oral |